Immune checkpoint inhibition to activate exhausted nonmalignant T cells (PD-1/PD-L1 axis) or modulation of the CD47-SIRPalpha axis to promote macrophage antitumor immune responses are other promising novel therapies of cutaneous T-cell lymphomas. The gene discussed is SIRPA; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.